MACK Merrimack Pharmaceuticals Inc.

-0.08  -1%
Previous Close 5.65
Open 5.68
Price To Book 1.19
Market Cap 74319307
Shares 13,342,784
Volume 92,449
Short Ratio 12.5
Av. Daily Volume 64,361

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2018.
HER2 negative metastatic breast cancer
Phase 2 data released June 25, 2018 - endpoints not met.
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due 2H 2018.
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
Cancer - front line pancreatic
Phase 1 safety data due 2H 2018.
Solid tumors
Poster at ASCO June 2018.
Solid tumors

Latest News

  1. Merrimack Receives $5 Million Milestone Payment from Shire
  2. Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue?
  3. Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
  4. Edited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMT
  5. highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank
  6. Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasizes Economic Growth
  7. Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2
  8. Merrimack (MACK) Reports Wider-than-Expected Q2 Loss
  9. Merrimack Reports Second Quarter 2018 Financial Results
  10. Merrimack Pharmaceuticals, Inc. to Host Earnings Call
  11. Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?
  12. Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call
  13. Ex-biopharmaceutical employees convicted in U.S. of insider trading
  14. Merrimack Secures $25 Million Debt Facility with Hercules Capital
  15. Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
  16. Ex-Akebia employee jailed for night as insider trading trial starts
  17. Merrimack Crashes as Phase II Pancreatic Cancer Study Fails
  18. Merrimack to scrap development of pancreatic cancer treatment
  19. UPDATE: Merrimack Pharma shares slide 34% after trial of pancreatic cancer treatment fails to meet main goals
  20. Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer